AtheroGenics (AGIX) Reports Positive Preliminary Results from Phase 3 Trial of ANDES
Tweet Send to a Friend
AtheroGenics, Inc. (Nasdaq: AGIX) released topline results from a planned interim analysis of its ongoing ANDES Phase 3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
